Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low – Here’s What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.80 and last traded at $2.8150, with a volume of 2991418 shares traded. The stock had previously closed at $2.89.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Bank of America decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The company has a 50-day moving average of $3.32 and a 200-day moving average of $3.97. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -2.35 and a beta of 1.05.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. During the same quarter in the prior year, the firm posted ($0.50) EPS. The business’s revenue was down 56.8% on a year-over-year basis. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the sale, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at $7,577,984.75. The trade was a 1.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00. Following the transaction, the director owned 6,199,863 shares of the company’s stock, valued at approximately $21,823,517.76. This represents a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 109,680 shares of company stock valued at $361,721 in the last quarter. 8.43% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of RXRX. International Assets Investment Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at about $39,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $41,000. MQS Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $41,000. Finally, Allworth Financial LP raised its stake in shares of Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.